Related Experiment Video

Updated: Apr 25, 2026

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

13.1K

miR-33a levels in hepatic and serum after chronic HBV-induced fibrosis

Chuan-Feng Huang1, Cheng-Chao Sun, Fang Zhao

  • 1Department of Occupational and Environmental Health, School of Public Health, Wuhan University, Wuhan, 430071, China.

Journal of Gastroenterology
|August 27, 2014
PubMed

Insights

MicroRNA-33a (miR-33a) is elevated in chronic hepatitis B patients and promotes liver fibrosis by activating hepatic stellate cells. This suggests miR-33a as a potential therapeutic target for liver fibrosis.

Area of Science:

  • Hepatology
  • Molecular Biology
  • Biochemistry

Background:

  • Chronic hepatitis B virus (HBV) infection poses a significant healthcare challenge, leading to liver disease and mortality.
  • MicroRNA-33a (miR-33a) is known to regulate lipid metabolism, but its role in liver fibrosis remains unexplored.

Purpose of the Study:

  • To investigate the role and underlying mechanisms of miR-33a in the development of liver fibrosis.
  • To explore miR-33a as a potential biomarker and therapeutic target for liver fibrosis.

Main Methods:

  • Quantitative real-time PCR (qRT-PCR) was used to measure miR-33a expression in liver and serum samples from chronic hepatitis B patients.
  • Murine models of hepatic fibrosis were established, and primary human and murine liver fibrosis-associated cells were isolated and treated with transforming growth factor-β1 (TGF-β1).

Main Results:

  • miR-33a expression levels increased with fibrosis progression in human liver tissue and positively correlated with advancing hepatic fibrosis in serum.
  • miR-33a was significantly upregulated in hepatic stellate cells (HSCs) upon TGF-β1 stimulation.
  • Increased miR-33a enhanced TGF-β1's activation role in LX-2 cells, potentially by modulating Smad7 expression.

Conclusions:

  • miR-33a may serve as a novel biomarker for hepatic stellate cell activation and liver fibrosis progression.
  • miR-33a presents a potential new therapeutic target for managing liver fibrosis.
Abstract

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K
A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

5.2K

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
29
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
24
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
78
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
379